Method for preparing enrofloxacin pillared hydrotalcite

Abstract

The invention discloses a method for preparing enrofloxacin pillared hydrotalcite. The method comprises the following steps: dissolving enrofloxacin in a four-port flask by using a NaOH solution, adding deionized water, and regulating the pH value to 9.66; dropwise adding Mg-Al-NO3-LDHs slurry into an alkaline solution of enrofloxacin under N2 protection conditions, controlling the pH value to 7.5-11, wherein the ratio of enrofloxacin to hydrotalcite is 2:1; and aging under the condition of T=50-70 DEG C for 12 hours, centrifuging, washing, and performing vacuum drying, thereby obtaining the product. According to the method disclosed by the invention, by utilizing exchangeability of negative ions between hydrotalcite layers, enrofloxacin anionic model drug intercalation with functional characteristics is assembled into the interlayer of hydrotalcite, a drug-inorganic composite material is synthesized and has an excellent in-vitro release effect, so that after an antibiotic medicine enrofloxacin is inserted into the hydrotalcite interlayer, cumulative toxicity and side effects of the medicine in vivo are reduced on the basis of reducing raw drug activity, the administration frequency is reduced, compliance in the animal body is increased, and the application range of the hydrotalcite in a biological material is widened.

Description

technical field [0001] The invention relates to a preparation method of a novel organic medicine-inorganic composite material enrofloxacin pillared hydrotalcite. Background technique [0002] With the development of science and the advancement of science and technology, people's requirements for the treatment effect and treatment methods of diseases are also increasing day by day. Improving the efficacy, simplifying the way of medication, and reducing side effects are still the focus and direction of research by scientists. Especially for the highly toxic drugs, in order to facilitate the patient to take the drug, while ensuring the effective therapeutic concentration, reduce the toxic and side effects of the drug, and avoid the generation of drug resistance, the drug can be made into a sustained-release preparation, so that the patient can use the drug in a sustained-release preparation. Sustained drug release over a longer period of time. There are two main types of sust...

AI Technical Summary

Problems solved by technology

However, these dosage forms are mostly common preparations. In clinical practice, the number of administrations is often high, the time of action in the body is short, and there are peaks and valleys of blood drug concentration. The side effects are relatively large, and the cost is high.

[0007] In recent years, enrofloxacin is generally considered not to stay in the animal body, but it has a certain accumulation when applied in large doses. The main metabolites in the body are enrofloxacin prototype and ciprofloxacin, and ciprofloxacin also has antibacterial activity , and the formation and elimination are slow and widely distributed. There are more and more reports of adverse reactions and drug resistance in veterinary applications, which can cause toxic side effects such as neurotoxicity, renal function damage, and allergic reactions. Enrofloxacin mainly Excreted via the kidneys and secondarily via the bile, thus remaining primarily in the muscles, liver and kidneys

Images